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ABSTRACT 24 
 25 
Objectives: Stage 1: Identify the impact of Joint Hypermobility Syndrome (JHS) on 26 
adults; Stage 2: Develop a questionnaire to assess the impact of JHS; Stage 3: 27 
Undertake item reduction and establish the questionnaire’s concurrent validity. 28 
Design: A mixed methods study, employing qualitative focus groups and interviews 29 
(Stage 1); a working group of patients, clinicians and researchers, and ‘think aloud’ 30 
interviews (Stage 2); and quantitative analysis of questionnaire responses (Stage 3). 31 
Setting: Stages 1 and 2 took place in one secondary care hospital in the United 32 
Kingdom (UK). Stage 3 recruited members of a UK-wide patient organisation. 33 
Participants: A total of n=15, n=4, and n=615 participants took part in Stages 1, 2 34 
and 3 respectively. Inclusion criteria were: ≥18 years; a diagnosis of JHS; no other 35 
conditions affecting physical function; able to give informed consent; and able to 36 
understand and communicate in English.  37 
Interventions: None. 38 
Main outcome measures: The development of a questionnaire to assess the 39 
impact of JHS.  40 
Results: Stage 1: A wide range of impairments, activity limitations and participation 41 
restrictions were identified. Stage 2: A draft questionnaire was developed and refined 42 
following ‘think aloud’ analysis, leaving 94 scored items. Stage 3: Items were 43 
removed on the basis of low severity and/or high correlation with other items. The 44 
final ‘Bristol Impact of Hypermobility’ (BIoH) questionnaire has 55 scored items and 45 
correlated well with the Physical Component Score of the Short Form 36 health 46 
questionnaire (r=-0.725). 47 
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Conclusions: The BIoH questionnaire demonstrated good concurrent validity. 48 
Further psychometric properties need to be established.  49 
 50 
Key words: Hypermobility, joint; Joint laxity, familial; Questionnaires; Interview; 51 
Focus Groups; Validity of results. 52 
 53 
 54 
  55 
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MANUSCRIPT 56 
 57 
TITLE 58 
Development and initial validation of the Bristol Impact of Hypermobility (BIoH) 59 
questionnaire  60 
 61 
 62 
INTRODUCTION 63 
Joint Hypermobility Syndrome (JHS) is a heritable connective tissue disorder 64 
characterised by excessive joint range of motion and pain [1]. It has been reported to 65 
affect up to 5% of women and 0.6% of men [2], although there is a lack of good-66 
quality epidemiological evidence for the true prevalence of JHS in the general 67 
population. The prevalence in musculoskeletal practice contexts is likely to be very 68 
high, however, with 30% of those referred to a Musculoskeletal Triage Clinic in the 69 
United Kingdom (UK) meeting the Brighton diagnostic criteria [3,4]. 70 
 71 
JHS is associated with a wide range of problems including pain, fatigue, 72 
proprioception deficits and repeated cycles of injury, anxiety and catastrophizing [5]. 73 
It may also be associated with a range of autonomic and gastrointestinal symptoms, 74 
and functional difficulties indicative of developmental coordination disorder/dyspraxia 75 
[6]. Empirical data has shown that, when compared with healthy controls, JHS has a 76 
significant impact on outcomes such as exercise endurance, gait, pain, 77 
proprioception, strength, function and quality of life both in children [7,8,9,10] and 78 
adults [11,12,13,14]. A recent systematic review and meta-analysis confirmed the 79 
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impact of JHS on a range of psychological variables such as fear, agoraphobia, 80 
anxiety, depression and panic disorders [15]. 81 
 82 
Physiotherapy, particularly exercise, is a mainstay of treatment for JHS, although 83 
recent systematic reviews highlighted the lack of research evidence [16,17]. The 84 
trials in adults included in those reviews used a range of patient reported outcome 85 
measures (PROMs), including the Short-Form 36 (SF-36) [18], the Arthritis Impact 86 
Measurement Scales 2 (AIMS-2) [13] and a questionnaire developed by Barton and 87 
Bird [19]. Of those, only the SF-36 captured improvements following exercise [18]. 88 
Only one of the five AIMS-2 subscales changed with exercise [13] and there were no 89 
changes evident in Barton and Bird’s questionnaire [19]. So, if exercise is effective 90 
(which has yet to be convincingly demonstrated [16]), only the SF-36 seemed to 91 
demonstrate sufficient measurement sensitivity. Closer inspections of these PROMs 92 
identify a lack of face, content and construct validity [20] for many issues reported by 93 
people with JHS [5]. For example Barton and Bird’s questionnaire [19] focused on 94 
lower limb activity (such as going up and down stairs, squatting, standing up and 95 
walking), failing to reflect upper limb functional difficulties. Neither the process of 96 
development nor the psychometric properties of the questionnaire were reported. A 97 
recent survey of physiotherapy practice in the UK [21] highlighted a lack of 98 
congruence between the aims of physiotherapy management for JHS and the tools 99 
used to assess the effectiveness of management. There is therefore a need to 100 
develop a condition-specific, psychometrically sound, outcome measure to underpin 101 
future research and clinical practice in this area. 102 
 103 
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This project had a number of related aims. Stage 1: To identify the impact of JHS on 104 
adults with the condition to inform initial patient-specific questionnaire items; Stage 2: 105 
To develop a questionnaire to assess the personal impact of JHS; Stage 3: To 106 
reduce the number of questionnaire items and establish the concurrent validity of the 107 
new questionnaire against the SF-36. 108 
 109 
 110 
METHOD 111 
Ethical approval was obtained from the South West 5 NHS Research Ethics 112 
Committee (10/H0107/46). The research was conducted in three stages as follows.  113 
 Stage 1 – Identification of questionnaire items. Methods: focus groups and 114 
telephone interviews with people with JHS. 115 
 Stage 2 – Development of the initial questionnaire. Methods: working group of 116 
patient research partners and researchers; ‘think aloud’ evaluation. 117 
 Stage 3 – Item reduction and validation of the questionnaire. Methods: 118 
administration of the initial questionnaire and SF-36 to members of the 119 
Hypermobility Syndromes Association (HMSA), a UK-based patient organisation; 120 
item removal; assessment of the concurrent validity of the final questionnaire 121 
items against the SF-36; production of the final questionnaire. 122 
 123 
Participants 124 
Inclusion criteria (Stages 1-3): Diagnosed with JHS; ≥18 years old; no other formally 125 
diagnosed conditions affecting physical function (such as inflammatory arthritis, 126 
osteoarthritis or neurological conditions); able to give informed consent; able to 127 
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understand and communicate in English. Stage 2 also recruited all five members of 128 
the research team.  129 
 130 
The sources of recruitment at each stage were as follows. 131 
Stages 1-2: Patients who met the Brighton criteria [3] for JHS (confirmed by a 132 
physiotherapist) who had been seen by the physiotherapy service at North Bristol 133 
NHS Trust in the previous two years were sent an invitation letter, participant 134 
information sheet and a reply slip. All participants completed informed signed 135 
consent. Two patient research partners (people with JHS who advised on the design 136 
and conduct of all aspects of the research, including the wording of patient 137 
information sheets and consent forms, and sat as equal members of a study steering 138 
group), and one further person with JHS who contributed to the working group during 139 
Stage 2 were recruited from the same cohort. 140 
Stage 3: Adult members of the HMSA were sent an invitation letter, participant 141 
information sheet and a copy of the questionnaires. Diagnosis of JHS was self-142 
declared. Completion and return of the questionnaires was taken as implied consent. 143 
 144 
Procedure 145 
Stage 1  146 
Two focus groups with people with JHS were conducted to explore the impact of the 147 
condition. An option to undertake a telephone interview was provided for those who 148 
were unable or unwilling to attend a focus group. A loose topic guide was used to 149 
steer the focus group and interview discussions. The same researcher (GG) 150 
conducted all focus groups and interviews, with another researcher (SP) taking notes 151 
during the focus groups to aid transcription. Focus groups and interviews were 152 
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audio-recorded, transcribed verbatim and anonymised. Open coding of the 153 
transcripts was used to identify individual questionnaire items, and codes were 154 
discussed in detail and verified by two researchers (GG and SP). Thematic analysis 155 
of the data did not progress beyond this first level of coding as the aim was limited to 156 
identification of individual items.  157 
 158 
Stage 2 159 
A working group was convened to develop the initial questionnaire. The group 160 
comprised three people with JHS (including two patient research partners) and five 161 
researchers. The researchers included clinical and academic expertise in 162 
physiotherapy and medical rheumatology and expertise in outcome measure 163 
development. Meetings were supplemented by e-mail and telephone 164 
correspondence and two researchers (GG and SP) took the lead in developing and 165 
revising draft questionnaires between meetings based on working group feedback 166 
and discussion. The working group initially discussed in detail the items developed 167 
from Stage 1 and agreed the specific wording of individual questions and response 168 
options, and the overall design of a first draft questionnaire. The three Bristol 169 
Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF-NRS) [22,23] were 170 
included with permission. The BRAF-NRS assess intensity of, effect of and coping 171 
with fatigue and, although developed for Rheumatoid Arthritis, have generic wording. 172 
This first draft questionnaire was then subjected to ‘think aloud’ analysis (also known 173 
as cognitive interviewing [24]) where people with JHS were asked to verbalise their 174 
thoughts whilst completing the questionnaire. This method was used to explore 175 
patients’ understanding of the questions and their responses to them. Interviews 176 
were audio-recorded, transcribed and anonymised. The transcriptions were analysed 177 
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question by question to identify any salient points and a report was produced for the 178 
working group. Further refinements were then made and the initial JHS 179 
questionnaire agreed with the working group. 180 
 181 
Stage 3 182 
An invitation letter, participant information sheet, a copy of the questionnaires (the 183 
initial JHS questionnaire, SF-36 and a demographics questionnaire) and a pre-paid 184 
return envelope were distributed by mail to all 1 502 adult members of the HMSA 185 
(identified by the membership secretary). No reminders were sent. Completed 186 
questionnaires were systematically entered into an IBM SPSS Statistics spreadsheet 187 
by a research associate employed on the project. Data accuracy was audited and 188 
verified by the lead author (SP). SF-36 scoring software v4.5 (Optum Insight) was 189 
used to calculate SF-36 component and subscale scores. Descriptive statistics and 190 
Kolmogorov-Smirnov tests for normality of data distributions were calculated for all 191 
items. A correlation matrix using Spearman’s Rank Correlation coefficients was 192 
produced to investigate the relationships between all scored items on the JHS 193 
questionnaire. Two criteria were then employed to inform decisions on whether to 194 
remove or retain individual items (although the BRAF-NRS were retained unaltered).  195 
1. Median score ≤40% severity. This criterion helped to identify items that were 196 
considered relatively less important. 197 
2. Strong correlations (r≥0.7) between individual items. This criterion helped to 198 
identify items that were potentially redundant (i.e. multiple items may have been 199 
measuring similar things). The wording of strongly correlated items were looked 200 
at closely and an iterative process was used to inform which questions should be 201 
retained and which should be removed.  202 
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The scores for the final JHS questionnaire items were then added to give a total 203 
score and this was correlated against the component and subscale scores of the SF-204 
36 to test concurrent validity. 205 
 206 
Given the pragmatic design of the questionnaire, including incorporation of the 207 
BRAF-NRS and the range of different response categories employed, it was 208 
considered inappropriate to try to identify separate domains within the JHS 209 
questionnaire using exploratory factor analysis.  210 
 211 
 212 
RESULTS 213 
Stage 1 214 
Stage 1 recruited 15 people with JHS and they contributed to two focus groups (both 215 
n=6/15) and telephone interviews (n=3/15). 13/15 (86.7%) were women. 2/15 216 
(13.3%) were aged 18-25 years, 7/15 (46.7%) 26-35 years, and 6/15 (40.0%) 36-45 217 
years. A wide range of issues related to the impact of JHS were raised, 218 
encompassing impairment, activity limitations and participation restrictions [25]. The 219 
issues identified included items common to many other long term musculoskeletal 220 
conditions, such as pain and fatigue and difficulties with standing, walking and 221 
negotiating stairs. However there were other more specific issues identified such as 222 
balance and coordination problems, unexpected pain, joints giving way and 223 
weakness. It was also clear that participants commented on both the intensity and 224 
frequency of issues. 225 
 226 
Stage 2 227 
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The working group devised a draft questionnaire relatively easily, using a mixture of 228 
numerical rating scales (similar to the BRAF-NRS) and Likert scales. It was decided 229 
that questions with common response options should be grouped together to 230 
facilitate navigation and completion and that larger scores should equate to greater 231 
impact. Four participants (all women, aged 19-40 years) took part in the think aloud 232 
analysis and the draft questionnaire was generally very well received, with the 233 
questions and response options generally clear. Participants stated that there was 234 
some repetition, with similar questions asked in slightly different ways, but the 235 
working group decided to keep all questions as part of Stage 3 was designed to 236 
identify closely correlated questions. The findings of the think aloud analysis 237 
informed a few minor changes to wording but was otherwise useful in confirming the 238 
face validity of the draft questionnaire. The individual questionnaire items and 239 
response options are evident from the final ‘Bristol Impact of Hypermobility’ (BIoH) 240 
questionnaire (supplemental material) and from Table 3 (those items that were later 241 
excluded). The resultant draft questionnaire contained 94 scored items (and a further 242 
10 identifying area of pain). 243 
 244 
Stage 3 245 
A total of 636/1 502 responses were received (42.3% response rate), of which 21 246 
were excluded (reasons for exclusion: 12 aged <18 years; 9 omitted at least one 247 
section of the JHS questionnaire meaning that a total score could not be calculated). 248 
The remaining 615 were included in analysis. 249 
 250 
Kolmogorov-Smirnov tests revealed that the data for age, individual JHS 251 
questionnaire items and the majority of SF-36 subscales deviated from normality (all 252 
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p<0.001). The only exception was the SF-36 Physical Component Score (p=0.200).  253 
Non-parametric analyses were therefore employed throughout.  254 
 255 
The median (IQR) age of participants was 39 (17) years. 81/599 (13.5%) were aged 256 
18-25 years, 156/599 (26.0%) 26-35 years, 186/599 (31.1%) 36-45 years, 100/599 257 
(16.7%) 46-55 years, 56/599 (9.3%) 56-65 years, 18/599 (3.0%) 66-75 years, and 258 
2/599 (0.3%) 76-85 years. Other participant characteristics are presented in Table 1. 259 
The majority were women (582/614, 94.8%) of white ethnicity (602/614, 98.0%). 260 
Participants were generally well educated (292/519, 56.3% had a university degree 261 
or equivalent) and a slight majority were in paid employment (339/600, 56.5%). 262 
 263 
Insert Table 1 here. 264 
 265 
Participants complained of pain in a wide range of painful areas (Table 2). Figure 1 266 
illustrates the total number of painful areas reported by participants. The median 267 
(IQR, range) number of painful areas was 8.0 (3.0, 0-10). 268 
 269 
Insert Table 2 here. 270 
 271 
Insert Figure 1 here. 272 
 273 
A total of 39 questions were removed on the basis of a median score ≤40% and/or a 274 
strong correlation with other questions (r≥0.7) (supplemental information 1).  275 
 276 
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The remaining 55 questionnaire items comprised the final ‘Bristol Impact of 277 
Hypermobility’ (BIoH) questionnaire and gave a single composite score of 360, with 278 
higher scores representing more severe impact (please see supplemental 279 
information 2 and 3). It takes approximately 10 minutes to complete. The median 280 
(IQR, range) BIoH score was 234 (81, 55-355). The total BIoH scores were 281 
correlated against the SF-36 scores to investigate concurrent validity and the results 282 
are presented in Table 3. 283 
 284 
Insert Table 3 here. 285 
 286 
The BIoH questionnaire correlated most closely with the Physical Component Score 287 
(PCS) (r=-0.725), reflecting less the Mental Component Score (MCS) (r=-0.447). 288 
This was also reflected in the subscales, with high correlation coefficients (r≥-0.7) for 289 
physical function, role physical and bodily pain. The only MCS subscale that had a 290 
strong correlation with the BIoH questionnaire values was social functioning. 88% 291 
(541/615) and 52% (320/615) of the cohort were below general population norms for 292 
the SF36 PCS and MCS respectively. There was no correlation between age and 293 
total BIoH score (Spearman’s Rank Correlation Coefficient r=-0.070, p=0.085). 294 
 295 
The median (IQR) BRAF-NRS scores for severity, effect and coping were 7.0 (2.0), 296 
7.0 (4.0) and 4.0 (4.0) respectively, indicating that people with JHS experience a 297 
high level of fatigue, it has a strong effect on their lives, but that they cope with 298 
fatigue relatively well. The mean (SD) values were 6.8 (2.1), 6.6 (2.6) and 4.1 (2.4) 299 
respectively. 300 
 301 
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 302 
DISCUSSION 303 
The new BIoH questionnaire is the first condition-specific tool validated for JHS. It 304 
was developed in close collaboration with people with JHS and seems 305 
comprehensive in reflecting items of importance. Scores correlate strongly with the 306 
PCS of the SF-36, with the strongest relationship being evident with Bodily Pain (BP) 307 
domain scores. Correlation with the MCS of the SF-36 was much more modest. This 308 
suggests that the BIoH questionnaire predominantly captures information about 309 
physical function rather than psychological function. Given the predominance of 310 
physical function items identified by focus group and interview participants, this 311 
seems an appropriate finding. It may be that further one-to-one interviews may have 312 
elicited further participation-level outcomes of importance to individuals, as such 313 
issues may be more difficult to discuss in a focus group context.  314 
 315 
There was a very high prevalence of pain in a wide range of body areas, many of 316 
which are not reflected in the current Brighton diagnostic criteria [3], such as the 317 
shoulders and neck. It should be noted that the wording of the BIoH questionnaire 318 
does not distinguish between unilateral and bilateral pain and therefore the actual 319 
number of areas is likely to be higher than reported here. However there was a clear 320 
trend towards participants reporting a high number of affected body areas, with the 321 
highest reported prevalence being of pain in all ten areas. Self-reported tender joint 322 
counts are used in other conditions such as rheumatoid arthritis (RA) and have been 323 
found to correlate well with clinician assessment [26]. It is difficult to directly compare 324 
data due to differing methodologies but Scott and Scott [27] reported that only 25% 325 
of consecutive people with RA (n=307) reported 6 or more tender joints out of 28 326 
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joints assessed. This threshold equates to just over 20% of the joints assessed. By 327 
way of comparison, 99.2% (609/614) respondents in the current study reported pain 328 
in 20% (two or more) of the 10 body areas assessed. In fibromyalgia the mean 329 
‘tender point’ count has been reported as 14.7 out of 18 [28], although these no 330 
longer form part of the diagnostic criteria and they include a mixture of joint and 331 
muscle points. Nevertheless the prevalence is akin to that identified for JHS in the 332 
present study. Clark et al [6] identified that 19% of people with JHS reported a 333 
concomitant diagnosis of fibromyalgia and therefore some overlap is to be expected. 334 
What is clear is that pain in multiple body areas seems to be a very significant issue 335 
in the JHS population described here. 336 
 337 
Terry et al [5] identified fatigue as one of the major factors associated with JHS. The 338 
BIoH questionnaire therefore included the three BRAF-NRS questions which assess 339 
fatigue severity, effect and coping. In RA the mean (SD) BRAF-NRS scores have 340 
been reported as follows (n=229): severity 6.8 (1.8), effect 6.5 (2.2), and coping 5.7 341 
(2.3) [22]. The present study has found that people with JHS seem to experience 342 
fatigue levels that are very similar to people with RA, certainly in terms of severity 343 
and effect. Interestingly, the coping with fatigue question is reverse scored, with 344 
patients choosing a lower score to represent worse coping. Many respondents in the 345 
present study seem to have scored this question inappropriately, choosing a high 346 
score when they had also chosen a high score for severity and effect (and vice-347 
versa). Our addition of a note on how to score this item may have caused some 348 
confusion for respondents. For the purpose of analysis the scores for this item were 349 
calculated as described by the developers [22] but there is a question mark over the 350 
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appropriateness of some responses. The very small contribution of this one item to 351 
the overall BIoH score is unlikely to have affected the findings. 352 
 353 
Although the results of the initial validation of the BIoH questionnaire are promising, 354 
it should be noted that other psychometric properties such as test-retest reliability, 355 
sensitivity to change and the minimum clinically important difference have yet to be 356 
established. Given its condition-specific focus, it is anticipated that the BIoH 357 
questionnaire will be sensitive to changes in physical function which is a key aim of 358 
physiotherapy management [21]. However this requires future verification.  359 
 360 
Limitations and strengths 361 
The response rate in Stage 3 (636/1 502, 42.3%) might have been improved through 362 
strategies such as sending reminders or providing an online response option. 363 
Respondents to Stage 3 included a slightly older age range than those who 364 
contributed to the Stage 1 development of the questionnaire items, although 71% 365 
were in the same 18-45 year age range (423/599) and no relationship was observed 366 
between age and total BIoH score. The proportion of women was largely similar 367 
between Stage 1 and Stage 3. Validation has therefore been conducted on a 368 
generally similar group to that which generated the questionnaire items. Members of 369 
the HMSA who responded to the questionnaire self-declared a diagnosis of JHS and 370 
this was not confirmed clinically. It should therefore be acknowledged that some 371 
respondents might have had other conditions. The questionnaire was not subjected 372 
to factor analysis to inform item reduction and questionnaire structure. The pragmatic 373 
design of the questionnaire, including the use of a range of different response 374 
options and adoption of the BRAF-NRS questions, complicated the effective use of 375 
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factor analysis for these purposes. In hindsight, a more standardised approach to 376 
response options might have facilitated further refinement of the questionnaire. The 377 
range of response options has also resulted in some items that attract a maximum 378 
score of 5 and others a maximum score of 10. The appropriateness of the relative 379 
weighting of questions is currently unknown, although the median total BIoH scores 380 
were almost identical when these items were scored out of 10 (median score 381 
234/360, 65.0%) as opposed to out of 5 (180.5/275, 65.6%). This is therefore 382 
unlikely to be a significant issue unless those items were to be affected differentially 383 
by an improvement or deterioration in the condition and this would need to be 384 
determined in future research. On a positive note, a very inclusive development 385 
process was employed which worked well. Initial validation has also been conducted 386 
on a very large sample size (n=615), although it should be noted that the sample 387 
lacked diversity with regards ethnicity, gender and educational attainment. 388 
 389 
Conclusion and future directions 390 
The new BIoH questionnaire has demonstrated initial potential to inform future 391 
research and clinical practice in this under-recognised and poorly managed 392 
condition. Future research needs to be conducted to determine other psychometric 393 
properties such as test-retest reliability, sensitivity to change, the minimum clinically 394 
important difference, and other aspects of validity, including Rasch analysis.   395 
 396 
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FIGURE CAPTION 493 
 494 
Figure 1. The total number of painful areas reported by individuals (n=614 valid 495 
responses). Participants were asked “During the past 7 days, have you had pain in 496 
any of the following areas?” and were given response options of ‘yes’ or ‘no’ to 10 497 
areas.  498 
  499 
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   1 
Characteristic  
(number of valid responses) 
Response  
(number of responses) 
% of valid responses 
Sex (614) Women (582) 94.8 
Men (32) 5.2 
Ethnicity (614) White (602) 98.0 
Mixed (5) 0.8 
Asian (2) 0.3 
Black (1) 0.2 
Chinese (1) 0.2 
Other (3) 0.5 
Relationship status (612) Single (177) 28.9 
Married/partner (378) 61.8 
Divorced/separated (48) 7.8 
Widowed (7) 1.1 
Other (2) 0.3 
24 
 
Living arrangements (595) Alone (96) 16.1 
With husband/ wife/ partner (356) 59.8 
With somebody else (143) 24.0 
Education* College diploma or equivalent (302/482) 62.7 
University degree or equivalent (292/519) 56.3 
Postgraduate degree (e.g. PhD) (76/392) 19.4 
Currently in paid employment 
(600) 
Yes (339) 56.5 
No (261) 43.5 
Hours of paid employment (324) Part-time (160) 49.4 
Full-time (159) 49.1 
Not applicable (5) 1.5 
Employment status (302) Self-employed (49) 16.2 
Employee (248) 82.1 
Self-employed and employee (1) 0.3 
Not applicable (4) 1.3 
25 
 
Table 1. Characteristics of responders to Stage 3. * More than one response could be selected so total n not reported and total 1 
% may be more than 100%. 2 
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 1 
“During the past 7 days, have you had pain in any of 
the following areas?” (number of valid responses) 
Number responding ‘Yes’ 
(% of valid responses) 
Back (613) 550 (89.7) 
Knees (611) 524 (85.8) 
Shoulders (611) 513 (84.0) 
Hips (610) 506 (83.0) 
Neck (601) 480 (79.9) 
Hands (605) 477 (78.8) 
Wrists (604) 470 (77.8) 
Feet (606) 439 (72.4) 
Ankles (603) 400 (66.3) 
Elbows (596) 292 (49.0) 
Table 2. Site of pain. Results are presented in order of frequency. 2 
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 1 
Question Reason for removal 
Median score  
≤40% 
Correlation  
≥0.7 
C. Please tick the box which best describes how much, during the past 7 days, hypermobility has affected… 
the clothing you have worn   
D. How often… 
have your hands seized up during the past 7 days?   
have you had difficulty getting comfortable in bed during the past 7 days?   
have you had trouble sleeping due to hypermobility during the past 7 days?   
has hypermobility kept you from your usual activities during the past 7 days?   
have you had difficulty walking a distance that would usually be OK for you during the 
past 7 days? 
  
has it been difficult to do your usual work activities (including unpaid work such as 
housework) during the past 7 days? 
  
has it been difficult to do your usual hobbies during the past 7 days?   
28 
 
E. How much difficulty have you had with the following tasks during the past 7 days due to hypermobility? 
Holding a mug or cup   
Doing up buttons   
Picking up a coin   
Washing dishes   
Using a door handle or lever   
Putting on socks   
Getting out of a car   
Making sharp turns while walking or running   
Pushing a shopping trolley or pushchair   
Getting dressed   
Raising your hands above your head repeatedly, e.g. to straighten hair or change a light 
bulb 
  
Turning over in bed   
Brushing or combing hair   
Pulling a light switch cord   
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Holding a frying pan   
Using a computer mouse or keyboard   
Getting out of bed without assistance   
F. How much discomfort would you have had after the following activities during the past 7 days? 
Climbing one flight of stairs   
Going down one flight of stairs   
Going up or down a flight of stairs without a handrail   
Walking at your own pace for 5 minutes   
Walking briskly for 5 minutes   
G. Please circle the number which best indicates… 
how able you have felt to cope with pain during the past 7 days   
thinking about what you are usually able to do, how much you have felt in control of 
your ability to do your usual activities during the past 7 days 
  
how much pain has interfered with your ability to take part in social or family activities 
during the past 7 days 
  
H. Please tick the box which best indicates your agreement with the following statements. 
30 
 
I am concerned about tripping or falling over when I am out and about   
I feel unsteady on my feet   
I feel anxious about falling or tripping   
I can control the position of my limbs   
I am able to cope with my pain    
I am able to manage my pain   
Supplemental information 1. Details of the removed questionnaire items and reasons for their exclusion.  = Met this 1 
criterion and used to inform removal of this item.  = Did not meet this criterion.2 
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 1 
SF36 Domains Median (IQR) Spearman’s Rank 
Correlation Coefficient (r) 
Physical Component Score (PCS) 31.9 (14.5) -0.725* 
 Physical Functioning (PF) 40.0 (45.0) -0.779* 
Role Physical (RP) 34.4 (43.8) -0.756* 
Bodily Pain (BP) 31.0 (29.0) -0.787* 
General Health (GH) 27.0 (30.0) -0.567* 
Mental Component Score (MCS) 44.1 (17.6) -0.447* 
 Vitality (VT) 25.0 (25.0) -0.624* 
Social Functioning (SF) 50.0 (50.0) -0.717* 
Role Emotional (RE) 75.0 (50.0) -0.476* 
Mental Health (MH) 65.0 (30.0) -0.455* 
Table 3. Median SF-36 component scores and correlation against the total 2 
BIoH score. * All p<0.001. 3 
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 2 
Figure 1.  3 
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Supplemental information 2. The Bristol Impact of Hypermobility (BIoH) 1 
questionnaire. 2 
 3 
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Supplemental information 3. The Bristol Impact of Hypermobility (BIoH) 1 
questionnaire scoring guidance. 2 
 3 
